Chemotherapy treatments for metastatic colorectal cancer: Is evidence-based medicine in practice?

Journal of Oncology Practice

Volumn 4, Issue 6, 2008, Pages 271-276

  Field, Kathryn M ^a,b,c   Kosmider, Suzanne ^a,b,c   Jefford, Michael ^a,b,c   Jennens, Ross ^a,b,c   Green, Michael ^a,b,c   Gibbs, Peter ^a,b,c  

^a WESTERN HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78650512846     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.0852002     Document Type: Article

References (38)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Colon Cancer. V. 1.2008. http://www.nccn.org/professionals/physician-gls/PDF/colon.pdf
3. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
4. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
5. Colucci G, Gebbia V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005
6. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - A GERCOR study. J Clin Oncol 24:394-400, 2006
7. Field K, Kosmider, Jefford M, et al: Chemotherapy (CT) dose adjustment for obese or elderly patients: How often does it occur, and should it? Results of an Australian survey. J Oncol Pract 4:108-113, 2008
8. Kosmider S, Field K, Jefford M, et al: Surveillance following treatment for colorectal cancer in Australia: Has best practice been adopted by medical oncologists? Intern Med J 38:415-421, 2008
9. Gamelin L, Boisdron-Celle M, Delva R, et al: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061, 2004
10. Muto O, Ando H, Ono T, et al: [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions]. Gan To Kagaku Ryoho 34:579-581, 2007
11. Cersosimo RJ: Oxaliplatin-associated neuropathy: A review. Ann Pharmacother 39:128-135, 2005
12. Hochster HS, Grothey A, Childs BH: Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25:4028-4029, 2007
13. a. Hochster HS, Grothey A: Magnetic resonance imaging versus bone scan in high-risk prostatic carcinoma: Some methodological considerations. J Clin Oncol 26:1189-1190, 2008
14. Goldberg RM, Sargent DJ, Morton RF, et al: Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J Clin Oncol 24:3347-3353, 2006
15. Damianovich D, Adena M, Tebbutt NC: Treatment of 5-fluorouracil refractory metastatic colorectal cancer: An Australian population-based analysis. Br J Cancer 96:546-50, 2007
16. Cassidy J: Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX? Nat Clin Pract Oncol 4:280-281, 2007
17. Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al: Phase III study of capecitabine plus oxaliplatin versus continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. J Clin Oncol 25: 4224-4230, 2007
18. Martoni AA, Pinto C, Di Fabio F, et al: Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial). Eur J Cancer 42:3161-3168, 2006
19. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413-1418, 1998
20. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352:1407-1412, 1998
21. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
22. Graeven U, Arnold D, Reinacher-Schick A, et al: A randomised phase II study of irinotecan in combination with 5FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma. Onkologie 30:169-174, 2007
23. Ychou M, Fabbro-Peray P, Perney P, et al: A prospective randomized study comparing high- and low-dose leucovorin combined with same-dose 5-fluorouracil in advanced colorectal cancer. Am J Clin Oncol 21:233-236, 1998
24. Jäger E, Heike M, Bernhard Het al: Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial - Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. J Clin Oncol 14:2274-2279, 1996
25. Cancer Institute New South Wales: New South Wales Cancer Institute cancer treatment guidelines. https://www.treatment.cancerinstitute.org.au
26. Maindrault-Goebel F, Lledo G, Chibaudel B, et al: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): A GERCOR study. J Clin Oncol 25:166s, 2007 (suppl; abstr 4013)
27. Kennedy JG, Donahue JP, Hoang B, et al: Vesicant characteristics of oxaliplatin following antecubital extravasation. Clin Oncol (R Coll Radiol) 15:237-239, 2003
28. Foo KF, Michael M, Toner G, et al: A case report of oxaliplatin extravasation. Ann Oncol 14:961-962, 2003
29. Baur M, Kienzer HR, Rath T, et al: Extravasation of Oxaliplatin (Eloxatin): Clinical Course. Onkologie 23:468-471, 2000
30. Jefford M, Jennens R, Speer T, et al: Different professionals' knowledge and perceptions of the management of people with pancreatic cancer. Asia-Pacific J Clin Oncol 25:44-51, 2007
31. Jennens RR, de Boer R, Irving L, et al: Differences of opinion: A survey of knowledge and bias among clinicians regarding the role of chemotherapy in metastatic non-small cell lung cancer. Chest 126:1985-1993, 2004
32. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947, 2000
33. Maindrault-Goebel F, Louvet C, Andre T, et al: Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 35:1338-1342, 1999
34. Sørbye H, Dahl O: Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. Acta Oncol 42:827-831, 2003
35. Cassidy J, Tabernero J, Twelves C, et al: XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22:2084-2091, 2004
36. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
37. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343:905-914, 2000
38. Delord JP, Pierga JY, Dieras V, et al: A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours. Br J Cancer 92:820-826, 2005